Many cancer-associated mutational signatures remain unexplained. Team CAUSE aims to connect DNA damage, mutational patterns, ...

WEE1 functions as a checkpoint gatekeeper; inhibition forces cell-cycle progression despite unrepaired DNA damage, leveraging tumor replication stress and p53/repair deficits to induce mitotic ...

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

(DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated ...

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA ...

There is one thing that is the leading cancer risk factor, responsible for 60 percent of all diagnoses - it outranks smoking, ...

Dr. Priya Hays discusses the mechanisms of treatment resistance in cancer, highlighting their significance for developing ...

Scientists uncover the ovarian cancer cause behind drug resistance and immune therapy failure - here's what the latest 2026 research means for The post From Gut Bacteria to DNA Repair: The Discoveries ...

Explore how space oncology could transform cancer treatment through microgravity research and innovative drug development ...

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of ...